ELK GROVE VILLAGE, IL--(Marketwire - August 20, 2009) -
Highlighted Links |
|
|
Wake Pharma US, Inc. announced today that it has been awarded the American Podiatric Medical Association (APMA) Seal of Approval for its innovative product, Wound-Be-Gone®, based on a revolutionary oxygen free radical binding technology.
In addition to the growing number of professional awards, Wound-Be-Gone® continues to receive patient and clinical testimonials from across the country. The “Wound-Be-Gone-ers” and wound care specialists alike are praising Wound-Be-Gone®:
“I am so grateful to have had the opportunity to use the product ‘Wound Be Gone.’ This product did for me in two days what took other methods three months, without any discomfort. I received a bypass surgery to avoid amputation on my left leg recently. When I saw my left leg wound un-bandaged after the first week, it brought tears to my eyes. I am a 50-year-old woman with diabetes and I lost my right leg to amputation a little over 18 months ago. I really think that if this product were available before, I would still have both of my legs today. ‘A special thank you’ for this wonderful gift of a brighter future!”
-- Tammy, current user of Wound-Be-Gone®.
“Recently, I have seen several patients in the new wound unit at the United Medical Center who presented as excellent candidates for the Wound-Be-Gone® wonder cream. I want to coin the term ‘Wonder Cream’ because I have seen a series of miraculous results. If at all possible, I would like to obtain more samples to try on these patients in the clinic. We are seeing at least 2 - 3 patients a week that can benefit directly from Wound-Be-Gone.”
-- Macy G. Hall Jr., MD. F.A.C.S, Director, Wound Care Center, Specialty Hospital of Washington, Washington, DC.
To view additional testimonials and clinical results from Wound-Be-Gone, please visit http://www.woundbegone.com/testimonials.php.
Wound-Be-Gone® is a new over-the-counter gel that demonstrates enhanced wound healing in varied clinical settings with both acute and chronic wounds. The mechanism of action appears to be related to a decrease in inflammatory mediators due to the active scavenging of oxygen free radicals. Visit www.woundbegone.com for more details.
About Wake Pharma US, Inc.:
Wake Pharma US, Inc. is an innovative and international company with its own manufacturing facility located in the European Union. Wake Pharma US, Inc. specializes in development, marketing and distribution of revolutionary and unique products to the health marketplace. For further information about Wake Pharma US, Inc. please visit our website at www.wakepharmaus.com.
Contact:
Maggie Jankowski
Email Contact
224-366-3902
1-888-333-7045